Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 15/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | DNM1L | O00429 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668319 | 0.93 | CFTR (0.38) | NPC1RAB9ASMN1; SMN2CFTRNR1I2 | |
| SCHEMBL3640725 | 0.89 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2CFTRNR1I2 | |
| SCHEMBL14038008 | 0.86 | CFTR (0.42) | NPC1RAB9ASMN1; SMN2CFTRNR1I2 | |
| SCHEMBL14038112 | 0.85 | CFTR (0.50) | NPC1RAB9ASMN1; SMN2CFTRNR1I2 | |
| SCHEMBL16422093 | 0.84 | CFTR (0.55) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL3636415 | 0.82 | GPR142 (0.41) | NPC1RAB9ASMN1; SMN2CFTRNR1I2 | |
| SCHEMBL3637763 | 0.82 | POLQ (0.39) | NPC1RAB9ASMN1; SMN2CFTRNR1I2 | |
| SCHEMBL14038066 | 0.82 | MAP4K1 (0.38) | NPC1RAB9ASMN1; SMN2CFTRNR1I2 | |
| SCHEMBL19225780 | 0.82 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2CFTRNR1I2 | |
| SCHEMBL16161230 | 0.80 | CFTR (0.42) | NPC1RAB9ASMN1; SMN2CFTRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| EP-2789606-A1 | Modulators of CFTR | Vertex Pharmaceuticals Incorporated (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789606-A1 | Modulators of CFTR | Vertex Pharmaceuticals Incorporated (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166516-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | NPC1 43/4885RAB9A 1483/4885SMN1; SMN2 4780/4885 |
| US-20150031708-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | NPC1 43/4885RAB9A 1483/4885SMN1; SMN2 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.